Research Article
Clinical and Immunologic Profiles in Incomplete Lupus Erythematosus and Improvement with Hydroxychloroquine Treatment
Table 1
Characteristics of ILE and SLE study groups.
| | Feature | ILE () | SLE () | |
| | Age (years) | 45.3 ± 1.6 | 37.3 ± 2.1 | 0.005 | | Female/male | 66/4 | 31/1 | 1.0 | | ACR criteria | | | 4 × 10−29 | | SLEDAI score | | | | | ANA (EU) | | | 0.30 | | Fatigue (mm) | | | 0.85 | | Pain (mm) | | | 0.33 | | mHAQ (0–3) | | | 0.22 | | Health status (1–5) | | | 0.0005 | | Rate current health (1–5) | | | 0.034 | | Hydroxychloroquine | 15 (21%) | 21 (65%) | <0.0001 | | Cyclophosphamide | 0 (0%) | 1 (3%) | 0.31 |
|
|
values are calculated by -test or Fisher’s Exact Test for dichotomized variables.
|
